Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhigang Han

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
The Journal of Infectious Diseases|March 15, 2026
Unnoticed Entry, Noticed Transmission: Epidemiological Insights into China's First clade Ib MPXV clusterXin Ye, Peng He, Baiyun Yu, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
The Journal of Infectious Diseases|March 15, 2026
Unnoticed Entry, Noticed Transmission: Epidemiological Insights into China's First clade Ib MPXV clusterXin Ye, Peng He, Baiyun Yu, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.
Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 12